Oxford Biodynamics PLC - Asset Resilience Ratio
Oxford Biodynamics PLC (OBD) has an Asset Resilience Ratio of 8.26% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Oxford Biodynamics PLC to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Oxford Biodynamics PLC's Asset Resilience Ratio has changed over time. See how leveraged is Oxford Biodynamics PLC's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Oxford Biodynamics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Oxford Biodynamics PLC.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX1.00 Million | 8.26% |
| Total Liquid Assets | GBX1.00 Million | 8.26% |
Asset Resilience Insights
- Limited Liquidity: Oxford Biodynamics PLC maintains only 8.26% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oxford Biodynamics PLC Industry Peers by Asset Resilience Ratio
Compare Oxford Biodynamics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Oxford Biodynamics PLC (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Oxford Biodynamics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-09-30 | 8.26% | GBX1.00 Million ≈ $121.67 |
GBX12.11 Million ≈ $1.47K |
+8.04pp |
| 2022-09-30 | 0.22% | GBX25.00K ≈ $3.04 |
GBX11.34 Million ≈ $1.38K |
-13.84pp |
| 2021-09-30 | 14.06% | GBX2.16 Million ≈ $263.17 |
GBX15.38 Million ≈ $1.87K |
-21.02pp |
| 2020-09-30 | 35.09% | GBX5.39 Million ≈ $655.44 |
GBX15.35 Million ≈ $1.87K |
-19.72pp |
| 2019-09-30 | 54.81% | GBX10.30 Million ≈ $1.25K |
GBX18.79 Million ≈ $2.29K |
-- |
About Oxford Biodynamics PLC
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more